From A SURVIVOR’s Perspective…

My name is Caralynn Hampson and I am SARC’s Research and Development Intern. I’m also a Ewing’s sarcoma survivor and future biostatistician. Thank you for supporting SARC.

Read more
New Study in Ewing Sarcoma Open to Enrollment

New Study in Ewing Sarcoma Open to Enrollment

SARC037 is a phase I study protocol to determine the recommended dose of trabectedin given as a 1-hour infusion in combination with low dose irinotecan. All patients enrolled will receive trabectedin combination …

Read more
Back to top